DPP4 and hydrops fetalis: Conversely, a large observational cohort study comparing DPP-4 inhibitors with glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) reported a 14% reduced risk of HF hospitalization among DPP-4 inhibitor users (HR = 0.86; 95% CI, 0.83–0.90), particularly for saxagliptin (HR = 0.74) and sitagliptin (HR = 0.92).22